Study on Belantamab Mafodotin with Nirogacestat, Lenalidomide, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• Must be 18 years or older.
• Must have a confirmed diagnosis of Multiple Myeloma.
• Must have received at least three previous treatments for multiple myeloma, including specific types of drugs.
• If you have had a stem cell transplant, it must have been over 100 days ago, and you should not have any active infections.
• Must have a performance status score of 0 or 1, or 2 if due to bone issues from multiple myeloma.
• Must have measurable disease based on specific medical tests.
• If you have tested positive for Hepatitis B, certain conditions must be met to participate.
• Can be on low-dose steroids or certain other medications.
• Must have a platelet count of at least 75 x 10^9/L.

Exclusion Criteria

• Have current eye disease, except mild conditions.
• Have heart-related health risks.
• Have allergies to the study drugs or similar medications.
• Have active infections needing treatment.
• Have used other monoclonal antibodies or anti-myeloma therapy recently.
• Have had recent radiotherapy or major surgery.
• Have had an allogeneic transplant or recent CAR-T therapy.
• Have received investigational drugs recently.
• Have severe side effects from previous treatments.
• Have had recent blood transfusions.
• Cannot receive live vaccines recently or during the study.
• Have active kidney issues or need dialysis.
• Have HIV unless specific conditions are met.
• Have uncontrolled digestive or skin diseases.
• Have electrolyte imbalances that can't be corrected.
• Have used a gamma secretase inhibitor before.
• Are taking certain medications that affect drug metabolism.
• Have had recent blood clots or bleeding issues.
• Cannot or will not take blood clot prevention medications.
• Stopped lenalidomide due to severe side effects.